How long is the appropriate time to take Carpiseti/Tsunkode tablets?

Capivasertib is an oral AKT inhibitor that mainly inhibits the growth and anti-apoptotic ability of tumor cells by blocking the PI3K/AKT signaling pathway. For patients with hormone receptor-positive, HER2-negative advanced breast cancer, the drug is often used in combination with fulvestrant to slow disease progression. There is no fixed course limit on the length of administration, and it depends more on the patient's individual response, disease control, and tolerance.

In clinical practice, most patients can begin to observe signs of disease stabilization or tumor shrinkage about 8 to 12 weeks after taking the drug. However, carpisetin is not a short-term medication, and its mechanism of action determines that it needs to continuously inhibit AKT signaling to maintain its efficacy. It is generally recommended that long-term use be maintained until the disease progresses or intolerable adverse reactions occur, provided the doctor evaluates the efficacy. Some studies have shown that patients who receive continuous treatment for more than half a year can achieve more lasting disease control effects.

In addition, taking medication regularly is crucial. Capisete is usually taken orally twice daily, and taking it on an empty stomach is more beneficial for drug absorption. If the patient experiences obvious adverse reactions, such as persistent high blood sugar or severe rash, the doctor may temporarily stop the medication or adjust the dose to ensure safety. Targeted therapy for breast cancer is often a "protracted battle." For patients who carry specific gene mutations, long-term administration of carpisetin can help delay disease progression and improve quality of life. Patients should not interrupt treatment on their own and should be followed up regularly for imaging evaluation and blood monitoring to ensure continued efficacy.

In general, the dosage cycle of carpisetin needs to be determined on an individual basis. Long-term maintenance therapy usually helps stabilize the disease as long as the patient tolerates it well. With the accumulation of more real-world studies, there will be clearer data to guide the optimal course of treatment and discontinuation strategies in the future, allowing this innovative targeted drug to more accurately serve breast cancer patients.

Reference materials:https://www.drugs.com/mtm/capivasertib.html